Cytocell to sell liquid FISH probes in Europe:
This article was originally published in Clinica
Executive Summary
UK company Cytocell is to manufacture and market a range of liquid FISH probes, in the same format as those previously distributed in Europe by Appligene Oncor, on behalf of its former parent company Oncor. According to Cytocell managing director Bruce Savage the exit of Oncor from the DNA FISH probe business left a gap in the market. Adderbury, Oxfordshire-based Cytocell will add to the Appligene Oncor range as part of its alliance with Appligene.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.